Biocon Limited, a prominent global biopharmaceutical company, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its biosimilar product, Pebrilzo™ (pertuzumab-qcay). This product is a biosimilar to Perjeta® (pertuzumab) and is designed to treat HER2-positive breast cancer, marking a significant enhancement of Biocon’s oncology portfolio in the United States.
Pebrilzo™ is a monoclonal antibody that targets HER2 receptors on cancer cells, aiming to provide a treatment option for patients suffering from HER2-positive breast cancer. The approval by the FDA underlines Biocon’s commitment to expanding access to high-quality biosimilars. Shreehas Tambe, CEO & Managing Director of Biocon Limited, highlighted the importance of this approval, stating that it represents a critical step in making affordable biologic medicines available to patients, thereby alleviating the financial burden associated with cancer treatment.
Earlier in September, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had also issued a positive opinion recommending the approval of Pebrilzo™ for use in Europe. This dual approval positions Biocon to potentially launch Pebrilzo™ in multiple markets, subject to the commercial launch timelines. Furthermore, Biocon has reached a global settlement and license agreement with Genentech, securing the earliest licensed launch date for Pebrilzo™ in the United States in the third quarter of 2028.
Biocon’s oncology portfolio now includes five biosimilar therapies approved in the United States, with Pebrilzo™ joining the ranks of Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). The company is also actively developing additional biosimilars, including those targeting trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, further strengthening its position in oncology treatment.
Analysts view Biocon’s strategic expansion into the biosimilar market as a positive move, given the increasing demand for cost-effective cancer treatments. The approval of Pebrilzo™ not only enhances Biocon’s competitive edge but also aligns with the global trend towards biosimilars as viable alternatives to high-cost biologics, potentially driving market growth and accessibility in the oncology sector.






